Gary Chung, MD
Ophthalmology · Federal Way, WANPI 1275642779
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 73.9% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $10,131, 9.5 times the $1,072 reported in 2019. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $108.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$12K
- Alcon$2K
- AbbVie$894
- Sun Pharmaceutical Industries Inc.$245
- Biotissue Holdings Inc.$203
- Dompe US, Inc.$155
- plus $746 from 13 others
What the payments were for
- Consulting fees$7,83847%
- Travel & lodging$1,5859%
- Food & beverage$7,33544%
- Education$180%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 43 | $12,414 |
| Alcon | 41 | $2,136 |
| AbbVie(2 entities) | 25 | $894 |
| Sun Pharmaceutical Industries Inc. | 13 | $245 |
| Biotissue Holdings Inc. | 5 | $203 |
| Dompe US, Inc. | 5 | $155 |
| Rxsight Inc | 2 | $146 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 6 | $116 |
| Heidelberg Engineering, Inc. | 1 | $71 |
| Oyster Point Pharma, Inc. | 2 | $64 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Sight Sciences, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Thea Pharma Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$7,088
- Travoprost Intraocular Implant - iDose$1,803
- KXL System$1,306
- iStent inject W$1,201
- Clareon$822
- IACCESS$533
- Clareon PanOptix Pro$413
- iDose$361
- XEN$351
- iStent$299
- Photrexa$251
- KXL1B-CE-marked KXLsystem$144
- ARGOS$127
- Rhopressa$125
- Rocklatan$125
- XEN GLAUCOMA TREATMENT SYSTEM$123
- CE-marked KXLA system$122
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$121
- Prokera$108
- AmnioGraft$108
How this compares
$16,793 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 273 | $244,173 |
| LumiganBimatoprost | 49 | $28,015 |
| Cyclosporine | 43 | $11,851 |
| Fluorometholone | 121 | $10,725 |
| Prednisolone Acetate | 162 | $7,502 |
| Loteprednol Etabonate | 35 | $4,399 |
| Latanoprost | 416 | $4,152 |
| MoxifloxacinMoxifloxacin Hcl | 98 | $2,806 |
| Brinzolamide | 12 | $2,739 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 161 | $2,586 |
| ValacyclovirValacyclovir Hcl | 55 | $2,052 |
| Ketorolac Tromethamine | 87 | $1,791 |
| Difluprednate | 16 | $1,737 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $1,475 |
| TafluprostTafluprost/Pf | 11 | $1,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $894 | $272,188322 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $34 | $4,39935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Federal Way
- Robert TesterFederal Way$11K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.